To investigate the impact of tumor anti-immunity on tumor development, we develop a simple tumor-immune model which incorporates the two-stage development of T lymphocytes (naive and effector cells). With qualitative analysis, we not only derive threshold conditions for the stability of the tumor-free equilibrium and for the existence of tumor-present equilibria, but also obtain some sufficient conditions to describe the dependence of the stability of tumor-present equilibria on the intensity of tumor anti-immunity. Combining these results with quantitative analysis, we find that tumor anti-immunity significantly enriches the dynamical behaviors which are absent in models without tumor anti-immunity. These behaviors include at most two tumor-present equilibria, stability switching phenomena, Hopf bifurcations (both supercritical and subcritical), homoclinic bifurcations, and saddle-node bifurcations of periodic solutions. Quantitative bifurcation analyses with the intensities of tumor anti-immunity and anti-tumor immunity as bifurcation parameters not only uncover complex dynamic behaviors of the model but also demonstrate discontinuous transitions in asymptotic states, such as transitions from the tumor-free equilibrium to a tumor-present equilibrium and from an equilibrium to a periodic oscillation. The results obtained highlight the significance of incorporating tumor anti-immunity response in comprehensively capturing the tumor-immune dynamics. They also provide new theoretical insights into tumor heterogeneity, immune escape, and potential therapeutic strategies targeting tumor immunosuppression.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: